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Mutation of the isocitrate-dehydro-
genase (IDH) enzymes is one of the 
central research topics regarding glio- 
magenesis. Indeed, 70% of gliomas 
are associated with a  gain-of-func-
tion IDH mutation and consequently 
synthesize the oncometabolite, 2-hy-
droxyglutarate (2-HG). This review 
aims to elucidate the effects of 2-HG 
on gliomagenesis. 2-HG promotes 
tumorigenesis by impacting metabo-
lism, vascularization and altering the 
epigenome of glioma cells. Glioma 
metabolism and vascularization is al-
tered by 2-HG’s effect on the stability 
of hypoxia-inducible factor (HIF) and 
inhibition of endostatin. However, 
2-HG’s impacts on epigenetic mech-
anisms are more profound to gliom-
agenesis. Through competitive inhibi-
tion of JHDMs and TET proteins, 2-HG 
orchestrates histone and DNA hyper-
methylation, which is associated with 
gene silencing and dedifferentiation 
of cells. The hypermethylator pheno-
type induced by 2-HG also results in 
alterations of the interaction of the 
immune system with the tumour. 
Additionally, this study reviews 2-HG 
promotion of tumorigenesis by inhib-
iting repair of DNA alkylation damage 
through competitive inhibition of AlkB 
proteins.
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Introduction
Gliomas, tumors derived from neural stem cells or glial progenitor cells, 
are a heterogenous group of brain tumors [1]. They are the most common 
type brain tumor, representing 50% of all brain cancers [2]. Median survival 
time for World Health Organization (WHO) classified grade IV malignant gli-
omas is 15 months, even with aggressive treatment [3, 4]. Glioma research 
was revolutionized in 2008, when the genetic sequencing of glioblastomas 
revealed that the mutation of isocitrate dehydrogenase 1 and 2 (IDH1/2) is 
a prevalent mutation in various glioma entities [5]. The most common IDH1 
mutation is R132H, while the most prevalent IDH2 mutations are: R172G, 
R172K, and R172M [6]. IDH1/2 catalyze the reaction isocitrate and NADP+ 
to α-ketoglutarate (α-KG) and NADPH+H. The gain of function IDH1/2 mu-
tations however allow the enzymes to reduce α-KG to the oncometabolite, 
2-hydroxyglutarate (2-HG) [7]. In the last years, 2-HG has become the cen-
ter of research, as this oncometabolite changes the tumor metabolism and 
alters the glioma epigenome [7, 8]. Different glioma entities have different 
rates of IDH1 mutations. The most common IDH1 mutated gliomas are an-
aplastic oligodendrogliomas WHO grade III and anaplastic astrocytomas 
WHO grade III with a 81.6% and 82% IDH1 mutation rate respectively [9]. 
However, only 3.1% of gliomas carry IDH2 mutations [9]. Interestingly, it was 
also established that IDH1 and IDH2 mutations are mutually exclusive in gli-
omas; barely any gliomas harbor both, IDH1 and IDH2 mutations [9]. This 
indicates at the severity of IDH1/2 mutation, as only one mutation is enough 
to mediate tumorigenesis.
The relevance of IDH1/2 mutations is also demonstrated by the WHO 
classification system, which was updated in 2016 to accommodate the ge-
netic makeup of the different glioma subtypes. Relevant to this review is the 
division between low-grade gliomas (LGG) (grade I and II) and grade III and 
IV gliomas, also known as high-grade gliomas [10]. Whereas grade I gliomas 
are benign, grade IV tumors, also known as IDH-mutant or IDH-wild-type 
glioblastoma, are refractory to chemotherapy and show more advanced 
characteristics of malignancy [11]. Grade II gliomas almost universally trans-
form to high-grade gliomas [12]. Regarding grade II–IV gliomas, the updat-
ed WHO classification of 2016 subdivides lesions according to molecular 
markers, such as the presence of IDH mutations or 1p/19q deletion [10]. Of 
importance for this review is also the differentiation between primary and 
secondary glioblastomas. While primary glioblastomas are de-novo tumors, 
secondary glioblastomas develop from low-grade diffuse astrocytomas or 
anaplastic astrocytoma [13]. The distinctive genetic marker of secondary 
glioblastomas is the IDH1 mutation, as over 80% of secondary glioblastomas 
illustrate IDH1 mutations compared to only 5% of primary glioblastomas 
[14]. Secondary glioblastomas are also associated with a hypermethylator 
phenotype and exhibit a better prognosis than primary glioblastomas [14]. 
Due to the strong association with IDH1 mutations, this review will focus 
particularly on the pathogenesis of secondary glioblastomas.
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2-hydroxyglutarate 
IDH1/2 mutations are one of the earliest known muta-
tions occurring during glioma formation [15]. When mea-
suring the catalytic activity of mutant IDH1, Dang et al. 
[7] observed a “1,000 fold decrease in catalytic turnover” 
from isocitrate to α-KG. Conversely, studies suggest that 
cancers harboring IDH1/2 mutations produced 2-HG con-
centrations 10 to 100 times the levels of cancers with wild 
type IDH [16]. Further, while wild-type IDH1/2 produces the 
reducing agent NADPH+H+ during the reaction isocitrate 
to α-KG, mutant IDH1/2 consumes NADPH+H+ during the 
catalyzation of α-KG to 2-HG [7] (Fig. 1). This is significant, 
as NADPH+H+ is an important metabolite for macromole-
cule synthesis and defending cells against reactive oxygen 
species [17]. IDH1/2 mutations could offset the cellular re-
dox reactions, promoting tumorigenesis [17]. 2-HG is a chi-
ral molecule, so D- and L-enantiomer forms exist (Fig. 1). 
In vivo and in vitro experiments established that mutant 
IDH1/2 produces almost exclusively D-2-HG [16]. Therefore, 
D-2-HG seems to be the enantiomer most relevant to tum-
origenesis. Intriguingly, while cancer cells produce almost 
only D-2-HG, numerous studies observed that in vitro, L-2-
HG is a more potent inhibitor of various enzymes and has 
a greater effect on cell proliferation [18–20]. While IDH1/2 
mutations have a variety of consequences on tumorigene-
sis, the correlation between remarkably high levels of 2-HG 
in gliomas led to much investigation of the specific effect 
of 2-HG on gliomagenesis. 
α-ketoglutarate dependent dioxygenases
Vital to the understanding of 2-HG’s role in tumorigen-
esis is the consideration of 2-HG’s similar structure com-
pared to α-KG. The keto group of α-KG is simply exchanged 
for a hydroxyl group in 2-HG [21]. Due to the structural 
similarity of both metabolites, 2-HG acts as a competi-
tive inhibitor to α-KG dependent dioxygenases [18]. There 
are over 60 known α-KG dependent dioxygenases which 
could potentially be inhibited by 2-HG [22]. Especially rel-
evant to cancerogenesis are the α-KG dependent dioxy-
genases which catalyze hydroxylation reactions, such as 
DNA demethylation, histone demethylation, sensing of 
hypoxia and DNA repair of alkylation damage [22, 23]. For 
α-KG dependent enzymes, 2-HG acts as a competitive in-
hibitor and can thereby influence glioma tumorigenesis. 
Hypoxia-inducible factors 
α-KG dependent dioxygenases also play an important 
role during O
2
-sensing in cells. Hypoxia-inducible tran-
scription factors (HIF 1–3) coordinates the body’s response 
to hypoxia, ranging from the formation of new blood ves-
sels to increased synthesis of red blood cells [24]. HIF-α 
is degraded through post-translational hydroxylation, 
catalyzed by prolyl hydroxylase (also called EGLN), a α-KG 
dependent dioxygenase [22]. All α-KG dependent dioxy-
genases require oxygen as a co-substrate. In the case of 
HIF-α, if oxygen is present, prolyl hydroxylase can hydrox-
ylate the prolyl residues on the HIF-α subunit. Von Hip-
pel-Lindau protein can now bind to the hydroxylated HIF-α 
subunit, which leads to ubiquitination and the breakdown 
of HIF-α in proteasomes [22]. There is conflicting research 
regarding the impact of 2-HG on HIF. 
On one hand, research has shown that 2-HG inhibits 
prolyl hydroxylase. A study conducted by Xu et al. [18] illus-
trated that in vivo, HIF-α1 levels increased after the knock-
down of wild type IDH, introduction of mutant IDH or 
IDH1/2 – isocitrate-dehydrogenase-1/2; α-KG – α-ketoglutarate; 2-HG – 2-hydroxyglutarate; JDHM – Jumonji C domain-containing histone demethylase; 
Me – methylated lysin residue on histone; TET1/2 – ten-eleven translocation enzymes 1/2; 5meCyt – 5-methylcytosine; 5hmeCyt – 5-hydroxymethylcytosine; 
ALKBH – α-KG-dependent alkB homolog; M – methylation-damage
Fig. 1. In physiological conditions, IDH1/2 metabolizes isocitrate to α-KG with the production of NADPH and CO2. Cancerous mutated IDH1/2 
synthesizes 2-HG and NADP+ from α-KG. 2-HG competitively inhibits numerous α-KG-dependent-dixoxygenases. Here illustrated is 2-HG‘s 
competitive inhibition of JHDMs and TET1/2, which results in histone and DNA methylation, respectively. 2-HG also inhibits ALKBHs, leading 
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addition of 2-HG. Other research groups also noticed the 
correlation between IDH1/2 mutations and elevated HIF-
1α expression [25–27]. Interestingly, it was also observed 
that L-2-HG is a more potent competitive inhibitor than 
D-2-HG [18]. This would make sense, as it has been report-
ed that L-2-HG is synthesized primarily by cells in hypoxic 
microenvironments and oxygen starved tissue has a spe-
cial need for angiogenesis to combat hypoxia [28]. Under 
these physiological hypoxic conditions, L-2-HG is produced 
predominantly by lactatedehydrogenase A (LDHA) and to 
a lesser extent by malatedehydrogenase 1 and 2 (MDH1/2) 
(Fig. 2) [28]. Nonetheless, both enantiomers stabilize HIF-α 
through competitive inhibition of prolyl hydroxylase and 
thereby promote tumorigenesis. This is because the same 
mechanisms that allow cells to survive during hypoxia 
help tumor growth, as HIF regulated genes increase an-
giogenic factors, glycolysis, glucose transporters, invasion 
factors and survival factors [29]. 
On the other hand, research also suggests that D-2-HG 
promotes HIF-1α degradation by stimulating prolyl hydrox-
ylase activity [19]. Koivunen et al. [19] obtained similar re-
sults as the papers mentioned above in regard to L-2-HG, 
as they observed that L-2-HG inhibited prolyl hydroxylase. 
Surprisingly however, this research group also describes 
that instead of inhibiting, D-2-HG potentiated prolyl hy-
droxylase catalytic activity, resulting in HIF-1α degrada-
tion. The paper reports that HIF-1α levels were reduced 
in human IDH-mutated proneural tumors, compared to 
IDH-wild type samples [19]. Other research groups also 
concluded that the addition of D-2-HG but not L-2-HG, re-
duced HIF-1α concentration in cells and that IDH mutation 
was not sufficient to upregulate HIF-1α concentrations in 
gliomas [30, 31]. Supporting, but not proving the higher 
prolyl 4-hydroxylase activity, IDH-mutated cancers are as-
sociated with heightened expressions of prolyl 4-hydroxy-
lases, which tag HIF-1α for ubiquitination and subsequent 
proteasomal degradation [32]. The consequence of this 
mechanism on tumor growth was also tested, as D-2-HG 
stimulates activity of prolyl 4-hydroxylase and subsequent 
HIF-1α degradation which reduced colony formation of im-
mortalized human astrocytes [19]. 
Concluding, on the one hand 2-HG was associated with 
HIF-1 stabilisation while other studies have also reported 
that D-2-HG induces HIF-1α degradation. In part, these 
conflicting results can be resolved by the discovery that D- 
and L-2-HG suppress factor-inhibiting HIF1 (FIH1) [33, 34]. 
If FIH1 suppresses activation of HIF-1α, then an inhibition 
of FIH1 through 2-HG is an alternative mechanism which 
can lead to HIF-1α stabilisation [33, 34]. Nevertheless, the 
opposing results show that the 2-HG impact on HIF-1α has 
to be clarified. 
Endostatin
Unlike HIF, endostatin is a natural inhibitor of angiogen-
esis, which reduces tumor vascularization and suppresses 
tumor growth [35]. Upregulation of tumor vascularization 
is an important step during gliomagenesis, as glioblas-
tomas are characterized by extensive angiogenesis [36]. 
Further, neovascularization is associated with higher ma-
lignancy grade and reduced post-operative survival in pa-
tients suffering from gliomas [36]. Similarly to HIF, endo-
statin synthesis is also affected by 2-HG accumulation in 
IDH-mutated gliomas. Endostatin is synthesized through 
prolyl-hydroxylation of collagen prolyl 4-hydroxylase [35]. 
As prolyl 4-hydroxylase is α-KG dependent, researchers 
postulate that 2-HG can competitively inhibit this enzyme, 
leading to lower concentrations of endostatin in IDH-mu-
tated gliomas [37]. In fact, IDH-mutated gliomas were 
associated with reduced levels of endostatin and higher 
rates of blood vessel densities [37]. The effect of 2-HG on 
endostatin was more directly confirmed by the observa-
tion that 2-HG injection into cells decreased endostatin 
levels [18]. Thereby, 2-HG promotes tumorigenesis by in-
hibiting endostatin, which then leads to tumor vascular-
ization and proliferation. 
Epigenetics during cancerogenesis 
While traditionally, 2-HG’s impacts on gliomagenesis 
have been associated with alterations to tumor metabo-
lism and vascularization, more recent research suggests 
that glioma formation is driven to a greater extent by 
epigenetic alterations induced by 2-HG. In essence, epi-
genetics describes modifications of chromatin structure 
which consequently alter gene expression. The chroma-
tin configuration influences whether DNA transcription 
machinery can access DNA to facilitate transcription [38]. 
Regarding gliomagenesis, the two most examined epigen-
etic mechanisms altering chromatin structure are DNA 
methylation and histone modification [39]. Depending on 
the histone methylated, chromatin structure is loosened 
to promote transcription, or tightened to suppress tran-
scriptional activities. For instance, trimethylation of lysin 
4 on histone 3 (H3K4me3) is associated with genes that 
are transcriptionally active, while trimethylation of H3K9 
(H3K9me3) at gene promoters is one of the chief epigen-
etic silencing mechanisms in mammalian cells [39]. DNA 
methylation occurs on the GpG Islands of the genome; 
these are repetitive sequences of DNA and comprise 60% 
of the promoters [40]. While histone modifications can 
either enhance or repress transcription, DNA methylation 
leads to gene silencing [39]. Adding to the complexity of 
epigenetic mechanisms, DNA methylation can impact his-
tone methylation and vice versa. While DNA methylation 
and histone methylation are often described as indepen-
dent entities, they can interact with each other to modify 
cellular transcription status [39]. 
α-KG dependent histone demethylase 
In 2009, Tsukada et al. [41] discovered a group of his-
tone demethylases named Jumonji C (JmjC) domain-con-
taining histone demethylase (JHDM), which in presence 
of α-KG and iron, demethylate lysin residues on histones. 
JHDMs are also known as Lysin (K)-specific demethylases. 
This group contains a variety of JHDMs, which demethylate 
different lysin residues. Due to 2-HG’s similar structure to 
α-KG, 2-HG competitively inhibits JHDMs (Fig. 2). The three 
most important JHDMs during gliomagenesis are JHDM1A 
(official symbol KDM2A), JMJD2A (KDM4A), and JMJD2C 
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(KDM4C). Xu et al. [18] reported that elevated 2-HG lev-
els from mutant IDH1 can inhibit multiple α-KG dependent 
histone demethylases in vivo and in vitro. As seen in other 
α-KG dependent dioxygenases, L-2-HG was found to be 
significantly more potent than D-2-HG [18, 42]. The effect 
of 2-HG on histone methylation was further demonstrated 
in vivo by the observation that IDH-mutated glioma sam-
ples with abnormally high 2-HG levels exhibited increased 
methylation marks of the following histones: H3K4, H3K9, 
H3K27 and H3K79 [18]. This observation was supported 
by other research groups as well [43]. The methylation of 
histones explored by these papers do not all orchestrate 
the same epigenetic effects; mono-methylation of H3K4, 
H3K27 and H3K79 are associated with gene activation, 
while trimethylation of H3K9, H3K27 and H3K79 suppress-
es transcription [44]. Current research is especially focused 
on the trimethylation of H3K9 (H3K9me3). While H3K9me3 
has long been known as an epigenetic silencing mecha-
nism, it also plays an important role during tumorigenesis. 
H3K9me3 inhibits transcription and promotes heterochro-
matin formation [45]. Intriguingly, H3K9me3 is associated 
with IDH1 mutation in different types of gliomas [43, 46, 
47]. Supporting this observation, in vitro experiments on 
cells of the central nervous system showed that IDH-mu-
tated astrocytes or murine neurosphere cultures exhibited 
enhanced H3K9me3 [43, 47]. Evidence further suggests 
that other mechanisms of histone methylation, other 
than inhibition of JHDMs, are important for gliomagene-
sis. The methyltransferase, Enhancer-of-zeste homolog 2 
(EZH2), which catalyzes the methylation of H3K27, is over-
expressed in cancers such as lung, breast, prostate, blood 
cancers and glioblastomas [48]. EZH2 was also found to 
be vital in glioblastoma cells to maintain stem-cell-like 
properties and therefore promote tumorigenesis [49]. This 
suggests that histone methylation in general is an import-
ant epigenetic mechanism orchestrating carcinogenesis, 
which delineates the importance of 2-HG induced histone 
methylation for glioma formation. The significance of his-
tone methylation to tumorigenesis is also evident from 
much research showing that histone methylation inhibits 
cellular differentiation. For instance, a study reported that 
the “introduction of mutant but not wild-type IDH1 into 
astrocytes resulted in the upregulation of nestin (and oth-
er genes associated with stem cell identity) at the time 
of DNA methylation increase and the adoption of a neu-
rosphere/stem-like phenotype” [43]. Regarding gliomas, 
IDH-mutated gliomas with methylated H3K9 exhibit lower 
levels of glial fibrillary acid protein (a protein important for 
central nervous system cell differentiation) and less cellu-
lar differentiation [47]. Moreover, the cancerogenic effect 
of histone methylation is supported by the consideration 
that histone methylation can impact DNA methylation 
[46]. For instance, Turcan et al. [43] observed that specifi-
cally H3K9me3 is associated with DNA methylation, which 
could in turn promote cellular proliferation. 
Ten-eleven translocation enzymes 
DNA methylation is an important characteristic of tu-
morigenesis, as cancer cells often exhibit atypical DNA 
methylation patterns, including global DNA hypomethyla-
tion and promoter hypermethylation [50]. Both effects are 
pro-tumorigenic, as hypomethylation leads to genome in-
stability, while promoter hypermethylation, amongst other 
things, silences tumor suppressor genes [50]. While DNA 
methylation is usually catalyzed by DNA-methyl-transfer-
ases, de-methylation is initiated by the three ten-eleven 
translocation enzymes (TETs 1/2/3) [51]. TETs are anoth-
er type of α-KG dependent dioxygenases [51]. De-meth-
ylation occurs in a two-step process. First, TET enzymes 
successively oxidize 5-methylcytosine to 5-hydroxymeth-
ylcytosine (5hmC), to 5-formylcytosine (5fC) and finally 
to 5-carboxylcytosine (5caC). The three oxidized meth-
yl-cytosines, 5hmC, 5fC and 5caC, are collectively coined 
“oxi-methyl-cytosines (oxi-mCs)”. Next, the modified cy-
tosines of 5fC and 5caC are exchanged for non-methylat-
ed cytosines through base excision, thereby restoring the 
un-methylated cytosine. Out of the three oxi-mCs, 5hmC 
is the most prevalent because only 1-10% of 5hmCs are 
further oxidized to 5fC and 5aC [52]. This is why 5hmC is 
often used as a marker to measure TET-enzyme activity. 
Explored more extensively in the following reviews, 5hmC 
is an important metabolite that contributes to cancer de-
velopment [53–55].
In fact, TET2 is described as a tumor suppressor be-
cause studies suggest that many solid cancers and 15% of 
myeloid cancers carry TET2 mutations [56–58]. The catalyt-
ic activity of TET enzymes is dependent on α-KG, thereby 
researchers hypothesized that 2-HG from IDH-mutated gli-
omas competitively inhibits TET proteins. In a study by Xu 
et al. [18], D-2-HG inhibited TET1 up to 47% and TET2 up to 
83%. Similar to the inhibition of prolyl hydroxylase, L-2-HG 
was more potent than D-2-HG. As expected from inhibi-
tion of a demethylating enzyme, high 2-HG and inhibition 
of TET de-methylation activity was associated with DNA 
hypermethylation (Fig. 2) [18]. Xu et al. [18] demonstrat-
ed that in vivo, 5-hmC was much lower in mutated IDH1 
glioma samples compared to wild-type IDH1, indicating 
the impaired function of TET to demethylase DNA in the 
presence of abnormally high 2-HG levels. These findings 
are supported by observations that IDH-mutated acute 
myeloid leukemia cells showed impaired TET2 functions 
and hypermethylated phenotypes [21]. Not only is there 
Fig. 2. 2-hydroxyglutarate (2-HG) is a chiral molecule, which exists in 
a L-(S)-2-HG and D-(R)-2-HG form. In cancers, mutated IDH1/2 gen-
erates almost exclusively D-(R)-2-HG from α-ketoglutarate (α-KG). 
L-(S)-2-HG is synthesised during hypoxic conditions through lactate-
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a clear correlation between 2-HG dependent TET inhibition 
and DNA hypermethylation, but there is also evidence that 
2-HG impairment of TET enzymes induces cancer forma-
tion. 2-HG induced hypermethylation silences tumor sup-
pressors and inhibits cellular differentiation [43, 59–61]. 
Turcan et al. [43] observed that the introduction of mutant 
IDH1 into astrocytes coincided with increasing DNA meth-
ylation and the adoption of a stem-cell-like phenotype. 
Another study compared TET2 mutant mice to IDH-mu-
tant mice exhibiting high levels of 2-HG. Both types, TET2 
mutant mice and IDH-mutant mice, showed “stem cell ex-
pansion and impaired hematopoietic differentiation” [60]. 
Finally, in a very recent study, induction of TET2 expression 
in glioblastoma cells upregulated genes associated with 
differentiation of neural cells, such as the brain fatty ac-
id-binding protein [61]. This suggests that inhibition of 
TET2 through 2-HG could impair nerve cell differentiation. 
Immune system
The relationship between cancer and the immune sys-
tem is another important factor driving tumorigenesis. 
Cancer cells apply various methods to circumvent host im-
mune surveillance in order to proliferate. 
Current research provides evidence of novel immune 
evasive mechanisms specific to IDH-mutated gliomas. 
Using orthotopic syngeneic low-grade glioma models, 
Kohanbasch et al. [62] discovered that 2-HG reduces the 
expression of STAT1. STAT1 is a regulator of the chemok-
ine, CXCL10, which in turn attracts CD8+ cytotoxic T-cells. 
Thereby, a 2-HG induced abatement of STAT1 reduces 
CD8+ T-cell accumulation at the tumor site. When im-
planting IDH-mutated low-grade glioma cell lines in syn-
geneic mice, the developing tumors showed lower rates of 
CXCL10 and less CD8+ T-Cell infiltration than tumors from 
IDH-wild type cells. The effects of 2-HG were directly test-
ed, as inhibiting 2-HG synthesis in IDH-mutated glioma 
cell lines resulted in an increase in CXCL10 levels and el-
evated expression of STAT1. Conversely, treatment of IDH-
wild type glioma cells lines with 2-HG resulted in reduced 
STAT1 expression [62]. A supplementary review of these 
findings can be found in the commentary by Lucca and 
Hafler [63]. Kohanbasch’s et al. conclusion is supported 
by another study revealing a negative correlation between 
pathological glioma grade and STAT1 gene expression [64]. 
Overall, healthy brain tissue shows significantly higher av-
erage expression of STAT1 than glioma tissue [64]. 
However, evidence suggest that rather than stimulating 
immunoevasion of glioma cells, 2-HG reduces the immu-
nosuppression usually associated with cancer and thereby 
impedes cancerous cell proliferation. IDH-mutated gliomas 
are associated with a more active immune system than 
non-IDH-mutated gliomas [65, 66]. Studies observed that 
IDH-wild type gliomas show a greater infiltration of immu-
nosuppressive cells, such as T-regulatory cells (T-Regs) and 
tumor-associated macrophages (TAMs), than IDH-mutant 
gliomas [65–67]. T-Regs infiltrate tumor tissue and inhibit 
T-cell toxicity while simultaneously suppressing tumor an-
tigen presentation by dendritic cells [68]. Moreover, while 
macrophages usually exhibit anti-tumorigenic functions, 
in response to the local tumor microenvironment, TAMs al-
ter their function and facilitate tumor growth instead [68]. 
This conclusion is supported by a recent study by Rahman 
et al. [69], who investigated expression of immunogenic 
markers in IDH-mutated glioblastomas. CD163, a mem-
ber of the scavenger receptor of the cysteine-rich (SRCR) 
superfamily, is a marker for M2 Macrophages, which are 
a subtype of anti-inflammatory TAMs [70]. IDH-mutated 
glioblastomas are associated with a significantly lower 
expression of CD163, which could reduce immunosup-
pression and suppress tumor growth [69]. For instance, 
CD163-positive cancer cells are potentially associated with 
a higher malignant potential in clear cell renal cell carcino-
ma [71]. In the tumor microenvironment, CD70, member of 
the tumor necrosis factor (TNF) family, functions as an im-
munosuppressive factor [72]. CD70 expression is also de-
creased in IDH-mutated glioblastomas, resulting in more 
anti-tumor immunoactivity [69]. This difference in tumor 
immune cell infiltration is particularly evident when com-
paring secondary glioblastomas to primary glioblastomas. 
Amankulor et al. [66] explored the reasons why second-
ary glioblastomas tumors exhibit less immunosuppressive 
tumor-associated cell infiltration than primary glioblasto-
mas. They posit that, through mechanisms not quite clear, 
2-HG increases methylation and thereby silences genes as-
sociated with the tumor-derived immune system. Conse-
quently, IDH-mutated gliomas with high levels of 2-HG ex-
hibit less immunosuppressive cell infiltration and a more 
active host immune system. As a result, the host immune 
system can induce an anti-tumor immune response, inhib-
iting tumorigenesis. Amankulor et al. postulate that the 
milder cancer progression of secondary glioblastoma pa-
tients is partly related to patients high 2-HG levels, which 
translate into a more immune-active phenotype that pro-
hibits cancer proliferation [66]. Additionally, some studies 
reported that through 2-HG induced promoter methyla-
tion, IDH-mutated gliomas illustrate a lower expression of 
the transmembrane protein, programmed death ligand-1 
(PD-L1), than IDH-wild type glioma cells [65, 67]. PD-L1, ex-
pressed on cancer cells, binds to the programmed death 
receptor-1 on T-cells, and consequently inhibits T-cell im-
munoactivity and leads to immunosuppression [73]. How-
ever, PD-L1 is only amplified in 0.3% of glioblastomas [74]. 
Thus, glioblastomas do not rely on PD-L1 as their main im-
munoevasive strategy.
AlkB homolog, α-ketoglutarate-dependent 
dioxygenase 
Cancer cells steadily have to adapt to a changing en-
vironment. Therefore, elevated mutation rates in cancer 
cells increase the genetic diversity of the tumor and allow 
cancer cells to express a phenotype which is best suited 
to their environment. Thus, it can be argued that DNA 
mutations within existing cancerous tissue can promote 
tumorigenesis [75]. These DNA mutations can result from 
methylation of DNA bases through environmental or en-
dogenous alkylating agents. The described microevolution 
of cancer is suppressed if DNA mutations, such as alkylat-
ed DNA bases, are repaired. In mammalian cells, DNA al-
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kylation is corrected by the de-alkylating enzymes, AlkB 
proteins, which remove methyl groups from 1-methyl-ad-
enine and 3-methyl-cytosine [76, 77]. 
AlkB proteins are α-KG and iron dependent di-oxygen-
ases [76]. Wang et al. [77] observed that D-2-HG inhibits 
the repair of methyl-adenine by ALKBH2 and ALKBH3 in 
vitro (Fig. 2). They point out that D-2-HG is a weak inhib-
itor of ALKBH at physiological concentrations. However 
in higher concentrations as of 0.5 mM, D-2-HG results in 
a 50% inhibition of ALKBH2 [77]. Xu et al. [18] support this 
hypothesis, as they write that “the molar ratio of R-2-HG 
(D-2-HG) and α-KG has been calculated as an average 373-
fold in glioma patients, enabling R-2-HG (D-2-HG) to exert 
its inhibitory effects”. From this it can be hypothesized 
that D-2-HG’s competitive inhibition of ALKBH elevates 
intra-cancerous mutation rate and promotes glioma mi-
croevolution. 
Intriguingly however, the inhibition of DNA repair mech-
anisms through D-2-HG enhances the effectiveness of 
chemotherapy. Wang et al. [77] observed that IDH1/2 mu-
tated glioma cells are more sensitive to alkylating chemo-
therapy and this sensitivity was abolished when D-2-HG 
production was disrupted. Another study explored the per-
formance of the alkylating chemotherapy, PCV (procarba-
zine, lomustine and vincristine), on patients with IDH-mu-
tated anaplastic oligodendrogliomas and IDH-wild type 
anaplastic oligoastrocytomas [78]. Here, patients with IDH 
mutations responded better to the alkylating agents than 
patients with wild-type IDH [78]. The study concludes that 
screening patients for IDH mutations is beneficial to deci-
pher if they would benefit from neo-adjuvant PCV treat-
ment [78]. In another paper, the overexpression of ALKBH2 
in glioblastomas resulted in a resistance to the alkylating 
agent, temozolomide. Knockdown of ALKBH2 increased 
sensitivity to temozolomide [79]. 
Conclusions
Ultimately, the oncometabolite 2-HG promotes cellular 
cancerogenesis in gliomas. While tumor metabolism and 
angiogenesis are also affected by 2-HG, epigenetic conse-
quences stemming from the 2-HG induced hypermethyla-
tor phenotype, especially associated with secondary glio-
blastomas, are chiefly responsible for tumor progression. 
Histone and DNA methylation promote gene silencing and 
lead to cellular dedifferentiation. A prominent example of 
the epigenetic alterations induced by 2-HG are the impacts 
on the immune system. However, this review has also elu-
cidated some controversies in current research. Some ar-
gue that 2-HG does not directly promote tumorigenesis, 
as certain publications observed 2-HG induced destabili-
zation of HIF and reduction of immunosuppressive cell in-
filtration. However, on the whole, these anti-tumorigenic 
effects of 2-HG are largely dispensable, because it seems 
they only translate into a slightly milder tumor progression 
of secondary glioblastoma patients; gliomagenesis occurs 
nonetheless. While the rough outlines of 2-HGs effects on 
gliomagenesis are becoming clearer, more extensive re-
search is necessary to fully elucidate the pathogenesis of 
IDH-mutated gliomas. Especially the impact of epigenome 
alterations and the interactions between histone and DNA 
methylation is still vague. Understanding the pathogene-
sis of gliomas is imperative in order to generate effective 
therapies for IDH-mutated gliomas.
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